GET DAILY SIGNALSImmunityBio (IBRX) Shares Drop -38.7% in 30 Days After Earnings Miss and Going-Concern Update
Key Takeaways
- ImmunityBio (IBRX) shares fell about 38.7% over the last 30 days, from $9.91 to roughly $6.07, extending a pullback that also leaves the stock down about 20.7% over the trailing quarter.
- The sharpest leg down followed third-quarter 2026 results on November 9, when revenue missed estimates and net product sales declined sequentially for the first time in nine quarters.
- Investor sentiment was further pressured by a renewed "going concern" disclosure and a widening net loss that included a non-cash fair-value charge.
- The sell-off occurred despite positive news, including an FDA label expansion for ANKTIVA and a late-stage trial hitting its primary endpoint in BCG-naïve patients.
- Profit-taking, insider-selling filings, and broader weakness across the oncology and cell-therapy sector amplified the decline.
- For additional detail on the company's valuation and expectations, explore its Price Targets, Earnings, and Forecast pages.
ImmunityBio (IBRX) Company Overview and Market Position
ImmunityBio, Inc. is a commercial-stage immunotherapy company focused on next-generation treatments designed to activate both the adaptive and innate immune systems against cancer and infectious diseases. Its flagship product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an IL-15 receptor agonist approved in combination with Bacillus Calmette-Guérin (BCG) for certain patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company's broader Cancer BioShield platform also includes adenovirus-vectored vaccines, natural killer (NK) cell therapies, and additional immunomodulators. Founded and led by Executive Chairman Patrick Soon-Shiong, ImmunityBio is closely watched by investors for its commercial ramp of ANKTIVA, label-expansion opportunities, and an expanding pipeline across lung cancer, glioblastoma, and hematologic malignancies. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ImmunityBio (IBRX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, IBRX declined approximately 38.7%, falling from a closing price of $9.91 on October 14 to about $6.07. The move was not a single-day event: the stock gave back ground through late October before accelerating sharply lower after its November 9 earnings report, when shares dropped roughly 15% to 19% in a single session. Over the trailing quarter, the picture is somewhat more moderate but still negative. From a closing level of $7.65 in mid-August, the stock is down about 20.7%, meaning the last month accounts for most of the three-month decline. The stock remains well above its 52-week low near $1.95 but sits far below its February 2026 high of $12.43.
What Drove IBRX Stock Price in the Last 30 Days
The dominant catalyst was ImmunityBio's third-quarter 2026 earnings report on November 9. Total revenue rose 53% year over year to $48.8 million, but it missed the roughly $59 million consensus estimate, and net product revenue of $48.7 million declined about 4% sequentially—ending eight consecutive quarters of sequential growth. GAAP loss per share of $0.18 also missed the consensus of $0.08, while net loss attributable to shareholders widened to approximately $184.6 million from $67.3 million a year earlier, partly due to a $77.9 million non-cash fair-value charge tied to a related-party convertible note.
Compounding the pressure, the company's 10-Q reiterated "substantial doubt" about its ability to continue as a going concern without additional funding. With about $334.3 million in cash and marketable securities at September 30, rising R&D and selling expenses, and a share count that has grown through at-the-market equity sales, funding and dilution concerns weighed on sentiment. A securities investigation announced by Bronstein, Gewirtz & Grossman in the following days added further overhang.
Notably, the decline coincided with favorable clinical and regulatory updates: on October 14, the FDA expanded ANKTIVA's label to include BCG-unresponsive NMIBC with high-grade papillary-only disease, and the company reported that its phase III QUILT-2.005 trial in BCG-naïve patients met its primary endpoint. The negative share reaction largely reflected a "sell-the-news" dynamic after a strong run-up, alongside insider-sale filings and sector-wide weakness in oncology names such as Iovance Biotherapeutics (IOVA).
What Drove IBRX Stock Performance Over the Last Quarter
The quarterly trend reflects a broader pattern of high volatility and profit-taking after a steep rally. Over the past year, IBRX roughly tripled, and its valuation expanded to a premium multiple of sales as investors priced in ANKTIVA's market opportunity. Through the summer and early autumn, the stock rallied on label-expansion hopes, a favorable FDA decision on papillary-only disease, and positive QUILT-2.005 data. However, the premium valuation left little room for error, and the November earnings miss—combined with sequential revenue softness and renewed going-concern language—triggered a sharp repricing. Sector rotation away from higher-beta biotech and cell-therapy names added to the quarterly decline. From what I see, this kind of volatility is common in early-commercial biotech names when expectations run ahead of results.
IBRX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important near-term catalyst is the company's plan to submit a supplemental Biologics License Application to the FDA by the end of 2026 for ANKTIVA in BCG-naïve NMIBC patients, following the positive QUILT-2.005 results. Investors will also watch whether ANKTIVA's U.S. product revenue resumes sequential growth, given that the Q3 dip raised questions about commercial momentum. Funding remains a central risk: future equity issuances could dilute shareholders, while reliance on related-party support and the convertible note held by Nant Capital adds complexity. International expansion, including recent approval in Israel and early European treatment activity, represents an additional growth lever. As always with clinical-stage and early-commercial biotech, regulatory decisions, trial readouts, and broader risk appetite in the sector will continue to drive meaningful swings in IBRX. I'm watching this closely for signs of stabilization in the commercial metrics.
Exploring Tickeron’s AI Trading Bots
For investors seeking a more systematic approach to market volatility, Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant strategies appear in this featured section. The bots vary widely in trading style, timeframe, and performance metrics, allowing users to compare approaches that range from short-term momentum to longer-horizon trend models. Exploring the page can help traders evaluate data-driven strategies that complement their own research. In my view, these tools provide a useful way to test ideas alongside fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IBRX's Stochastic Oscillator remains in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for IBRX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +12.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 212 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 87 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 47 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
IBRX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for IBRX entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.744) is normal, around the industry mean (3.498). P/E Ratio (-9.089) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement